- 2261.412
- +3.639+0.16%
PDD, Alibaba Shares Down as Biden Administration Cites Abuse of Trade Rules
10 Consumer Discretionary Stocks Whale Activity In Today's Session
10 Information Technology Stocks Whale Activity In Today's Session
Semiconductor Index Made a Comeback Despite Volatility! Which Stocks Have the Most Upside?
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Alibaba Dropped The AI-Powered English Version Of Taobao In This Country, App Quickly Soars To The Top Of The Charts In No Time
DingTalk is the first to benefit from AI.
Accelerate landing.
Technology stocks led the S&P to four consecutive gains, Oracle reached a new high after hours, the US dollar and US bonds fell, gold hit a new high, and commodities rose.
In August, the PPI in the United States showed a cooling down of inflation, and the market slightly raised its bets on the Fed's aggressive interest rate cuts. US stocks rose together, with Nvidia up nearly 2%, while NIO Inc and XPeng fell more than 5%. The European Central Bank cut interest rates for the second time this year, but maintained a restrictive policy. European bonds fell, and the euro rebounded from its four-week low. Commodities rose across the board, with US oil briefly rising by 3.7%, gold reaching a new high with a nearly 2% increase, palladium rising by over 4%, and copper experiencing its largest two-month increase.
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
EXCLUSIVE: AI To 'Turbocharge' Alibaba's Cloud In Bid To Rival Microsoft, Amazon, Says Strategist
New Additions to Roth MKM's ADR Portfolio for September
Alibaba Launches Cainiao Next-Day Delivery In Europe, Plans Global E-Commerce Hubs
Xiaopeng fought a turnaround battle.
Partial victory.
pdd holdings is working hard to please merchants
The "hundred billion reduction" policy is gradually being implemented.
NIO Surges Over 32% in Five Days, Is an EV Rebound on the Horizon?
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
These AI Stocks Have Survived Recent Turmoil, Outpacing Nvidia with Steady Upswings
Increasing customer volume? Taobao gradually opens WeChat Pay today. Currently, some merchants have already started using it.
Starting from today, all Taobao and Tmall merchants will gradually open WeChat Pay. Currently, merchants are being invited in batches. Some merchants can see the invitation to open in Qianniu, and once they agree, they can immediately start using it.
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.